#Global Trends – Page 19 – HEALTHCARE INSIGHTS

Key Development UK-based biopharmaceutical firm Mereo BioPharma and Sentynl Therapeutics (a rare disease commercial subsidiary of Indian pharmaceutical group Zydus... Read more

Tag: #Global Trends

Commercial Adaptation in the GLP-1 Era: Nestlé Leverages Artificial Intelligence and Nutritional Science to Develop Companion Product Portfolio for Weight-Loss Drug Users

Global Biosimilar Empire Expansion: Sandoz Signs $322 Million Licensing Deal with Shanghai Henlius for Biosimilar Copies of Repatha®, Benlysta®, and Erbitux®

Precision Oncology Clinical Readouts: AstraZeneca Announces Phase 3 Wins for Enhertu® and Orpathys®-Tagrisso® in NSCLC Amid Volrustomig Bispecific Setback

Intellectual Property Enforcement: Eli Lilly Files Federal Lawsuits Against Six Entities Over Illegal Commercialization of Experimental Obesity Drug Retatrutide

Rare Disease Licensing Agreement: Mereo BioPharma and Sentynl Therapeutics Execute Up to $475 Million Deal for Oral AATD-LD Candidate Alvelestat

Food Safety Governance: Acting US FDA Commissioner Reaffirms Consumer Confidence in Fresh Produce, Releasing Updated Ready-to-Eat Processed Produce Guidance

Expanding Ophthalmic Biosimilar Footprint: Samsung Bioepis Officially Launches Opuviz® (Aflibercept Biosimilar) Pre-Filled Syringe Across Europe

Domestic Biomanufacturing Infrastructure Expansion: Bristol Myers Squibb Selects Houston’s Generation Park for $2.3 Billion Multi-Modal Manufacturing Campus

Domestic Biomanufacturing Expansion: Bristol Myers Squibb Commits $2.3 Billion to Build High-Tech Manufacturing Campus in Houston, Texas

Facebook

Map

Online Members